Gartner heads into its May 5 Q1 results with shorts accelerating hard — and options traders piling on defensively alongside them.
Short interest has become the dominant pre-earnings signal. Shares short jumped 21% over the past week to 14% of the free float, a sharp move that took SI from a relatively contained ~11.5% level in mid-April to a fresh recent high. That acceleration is the standout: the level was elevated before, but the pace of the move since April 23 is what draws attention. The ORTEX short score has climbed to 63.2 from 57 at the start of the week, confirming the build. Borrow conditions offer no friction to the shorts — cost to borrow has actually eased over the past month to just 0.38%, and availability remains wide, meaning supply is not a constraint. This is a conviction short, not a squeeze situation.
Options positioning reinforces the same lean. The put/call ratio has pushed to 0.68, more than two standard deviations above its 20-day average of 0.53 — the most defensive reading in options on this name in months. The stock itself has declined 7.5% over the past month, closing at $146.40 on Friday, with the selling continuing through the week. Notably, close peers ACN finished the week flat-to-up, while , , and each fell 4-6% — suggesting sector-wide pressure, but Gartner's short build is more acute than the group.
The analyst community has shifted sharply to the sidelines. Goldman Sachs maintained its Neutral this week but slashed its target from $220 to $171 — a 22% cut — while Wells Fargo's Underweight carries a $140 target, now below the current price. Barclays trimmed to $150 in April. The Street consensus is "hold" with a mean target of $173, implying modest upside to current levels, but the direction of travel is unmistakably lower. Bears point to flat EBITDA margins forecast around 23.5% for FY26, decelerating growth in the high-margin Research segment, a 28% projected EPS decline year-on-year, and the creeping threat that enterprise clients divert budget toward GenAI tools rather than Gartner subscriptions. Bulls counter with the company's structural moat — its Research segment drives ~82% of revenues, the contribution margin has expanded steadily over many years, and the consulting business has historically proven resilient through downturns. EV/EBITDA has compressed to 7.6x, and the PE now stands at 10.9x trailing — the cheapest the stock has looked in some time.
The earnings history adds an important backdrop. Gartner's most recent print in February triggered a single-day decline of 22% and a five-day loss of 21%. Short sellers and options traders appear to have that outcome in mind as they build positions now. The May 5 release will test whether Q1 results can credibly reframe the growth and margin trajectory — or whether the February shock marked the start of a deeper derating.
See the live data behind this article on ORTEX.
Open IT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
